



## **FEATURES OF INVASIVE CERVICAL CANCERS – CERVICAL INTRAEPITHELIAL NEOPLASIA: OVERVIEW**

**Mustafayeva Feruza Abulovna<sup>1</sup>, Nuraliyeva Hafiza Otayevna<sup>2</sup>.**

<sup>1</sup>senior teacher of the department microbiology, virusology and immunology

Bukhara state medical institute, Bukhara, Uzbekistan.

<sup>2</sup>head of the department medical biology sciences

Tashkent Pharmaceutical Institute, Tashkent, Uzbekistan,

---

**Resume.** In a review of the current literature materials on the problem of occurrence and development of cervical cancer. The classification, the various methods of early diagnosis and their value at preinvasive forms of cervical cancer - cervical intraepithelial neoplasia.

**Keywords:** cervical cancer, atypical flat epithelial cells, adenocarcinoma, human papillomavirus.

---

**Relevance.** Although modern medicine, including the diagnosis and treatment of oncological diseases, is developing in rapid steps, there is no tendency to reduce tumor diseases around the world. Cervical tumors are no exception. [1].

Cervical tumor (CT) is one of the most common tumor diseases among women and currently ranks second among oncological diseases. [2, 3, 4, 5, 6].

It is known that up to 400 thousand new cases of invasive tumors are registered in the world every year, and up to 200 thousand women are prematurely losing their lives due to this disease, in the Russian Federation these numbers are 12 thousand and 6 thousand women, respectively. [7].

Urmancheeva A.F. and Ulrich E.A. according to [7] quoted by the S, the median age of women with invasive cervical tumors is 45-55 years (18 to 80 years old), while the median age of those who died from this disease is 55-60 years. The prospect of the disease depends on its level, the total 5-year residence time after the development of the disease in Europe is 60%. Vesnina E.L. [8] cervical tumor (CT) in the group of women aged 15-29 among people with , the incidence rate claims to have shown a 100% result in the last 10 years, compared to 50% in the 30-45 age group. There has also been a significant increase in delayed forms of CT in

*Section A-Research paper*

diagnosis and treatment, such as a 34.2% comparative percentage of CT-induced women at Level III-IV in 1990, 37.1% in 1992, 38.8% in 1995, and 39.7% in 2003. Apparently, the tendency to grow in the last 13 years has been preserved. A literature review found that preinvasive forms of CT - cervical intraepithelial neoplasia (cervical intraepithelial neoplasia - CIN) - are observed before invasive form of Bbo. This phrase was introduced into practice by Richart in 1968 and proposed to be divided into 3 degrees [8, 9]:

- light level - CIN1(light epithelial dysplasia)
- intermediate level - CIN1 (intermediate epithelial dysplasia)
- heavy level - CIN1 (heavy epithelial dysplasia)

Only then has the development of a preinvasive tumor (CIS - carcinoma in situ) been shown [8, 9]. In the 80s of the last XX century, different classifications (classifications) of cervical intraepithelial neoplasia were used in different countries, and this led to the fact that diagnosis and treatment in different clinics around the world did not coincide in results [8, 10]. In recent years, evaluation of atypical epithelial cells for the purpose of transport is becoming more common under the Terminology Bethesda Systems (TBS) system proposed in 1988 [11]. Under this system, 2 categories of intraepithelial injury are distinguished:

- low level LSIL (Low-grade sguamous intraepithelial lesion), this level corresponds to CIN1;
- high level HSIL (High-grade sguamous intraepithelial lesion), this level corresponds to CIN2-3.

Also "atypical flat epithelial cells of unknown origin" signaling - ASCUS " (atypical sguamous celli of undetermined significance - ASCUS) and atypical glandular cells of undetermined significance - ACUS [7].

The practice of using the cited case in disease diagnosis has shown that this classification is not ideal and is not free from disadvantages, since errors in differential diagnosis of HSIL and LSIL were in most cases very numerous. In view of these problems, the diagnosis, observation of patient women based solely on cytological data has led to negative results and a negative prospect of CIN delay. Ayhan A. et al. [12] according to the data given, about 10 million women with CIN3/CIS are identified in the world every year, that is, this figure is up to 20 times more than the diagnosis made as an invasive tumor. Cin has been found in

*Section A-Research paper*

1% of pregnancies as a stage of CT in women, with anomalous rates in surtma found in 5% of examined women. Urmancheeva A.F. [13] a clinical-laboratory examination of a total of 4230 pregnant women yielded data on the detection of CIN3 in 22 pregnancies from a Class III-IV rub on Papanykolau, with an extended diagnosis confirming cin 3 in 6 of them, one woman was diagnosed with a microinvasive tumor. Currently, the detection of CIN during pregnancy does not raise doubts, the results of the cited scientific work [14, 15] found that the frequency of detection of CIN3 in pregnant women was 3 out of every 10 thousand tested. The diagnosis of CIN as an early diagnosis of CT has always been the focus of researchers, since not only treatment, but also the prospect of the course of the disease, has been linked to a clear and correct diagnosis [16]. The CT, which is a method of political diagnosis, has long been considered cytological studies recognized by experts of the World Health Organization (WHO) [17], but in recent years new methods for determining CIN have been proposed and are being introduced into clinical practice. As you know, one of the simplest methods of cin diagnosis is colposcopy [18, 19, 20, 21]. In this method, patients are diagnosed with visual leakage point heights, a wide spread vascular network [22]. In addition, against the background of the appearance of veins expressed in pregnant people, white spots of the metaplated epithelium are detected, there is a separation of mucus from the enlarged pores of the glands that function in the body [7].

Avtandilov G.T. and co-authors [23] have also proposed ploidometric diagnosis on cytological drugs. According to some authors, increased vascularization, edema, lymphocytic infiltration, desiduo-qualitative reaction of stroma are observed in histological examination. The displacement of the squamous-prismatic angle of the epithelium towards the ectocervix is frequently detected. Multiple squamous epithelium can often be seen hyperplastically, with impaired cell differentiation, additional blood capillaries can be detected in the epithelium. It is characteristic of the migration of enlarged glands to the vaginal part of the cervix, metaplasia in the prismatic epithelium, increased secretion processes. A cytological examination found that cells had active cytolysis and large amounts of "naked nuclei" [7, 22].

Physiological changes in gestational time, indicated by the authors above, are regressed 2-4 months after delivery and enter CIN hyperdiagnostics, leading to a "false" positive result. This leads not only to additional treatment procedures, but also to mental injury of the patient, but, in combination, CIN hypodiagnostics is also dangerous. Given these data, diagnosis injection into CIN using only Cytological and colposcopic examinations can lead to unsatisfactory results on the prospect of diagnosis and disease [20]. For this reason, the development and

*Section A-Research paper*

implementation of convincing diagnostic methods of identifying CIN in pregnant and non-pregnant women has not yet lost its relevance. Given these data, diagnostic injection into CIN using only cytological and colposcopic examinations can lead to unsatisfactory results on the prospect of diagnostics and disease [20]. For this reason, the development and implementation of convincing diagnostic methods of identifying CIN in pregnant and non-pregnant women has not yet lost its relevance.

One of the proposed new and future methods in medical practice is computational morphometry of cytological diagnosis. When morphological indicators of women with cervical dysplasia are studied, it is found that the nuclear area is up to 695  $\text{mkm}^2$ , and the cell area is enlarged to 3881  $\text{mkm}^2$ . The nuclear-cytoplasmic ratio becomes 2 times larger. In the unchanged epithelial cell in the normal state, however, the nuclear area is 212  $\text{mkm}^2$ , and the cell area is 442 to 3628  $\text{mkm}^2$ . As the pathological process becomes more expressed, the heterogeneity of the cell population increases [24, 25].

One of the modern methods proposed for the purpose of diagnosis is the immunogistochemical method used in differential transport of endocervical glandular epithelium, cervical duct and endometrial adenocarcinoma [26] as well as CIN [27, 28] safe, tumor - acquired lesions. There is also data on studies using the immunogistochemical method of detecting monoclonal antibodies (RSNA), c-erbB-2 oncogene, cyclin D1 and R53 mutant protein in relation to the nucleus protein of proliferating cells, studying the aggressiveness and virulence of non-cervical flat cell tumors. Evidence of biological activity of tumor cells is believed to have a positive response of antibodies to c-erbB-2 and r53 oncogene in much of the observations [26, 29]. Also, one of the proposed methods is to carry out a test on the diagnosis of HPV (human papilloma virus - human papilloma virus), since the transmission of HPV is a mandatory condition for the development and development of CIN and CT. [17, 30, 31]. Currently, the following 2 methods are mainly used to detect HPV infection in women: polymerase chain reaction (PCR) and hybridization method [32, 33]. It is important to note that in a Real-time PCR Examiner, HPV is an important method for determining the status of DNA [34, 35]. Detection of HPV types, viral loading, and viral DNA status is a method that determines the prospect of neoplastic progression [32, 36].

Vesnina E.L. [8] according to the data cited HPV screening in patients with changes in cytological lubricants allows the separation of a group with high risk HPV infection and a high probability of detection of CIN2,3. It is known that the

Section A-Research paper

E6 and E7 genes of HPV activate cellular telomerase with very high levels of HSIL da. The expression of telomerase RNA and viral oncogenes is inextricably linked with the aggravation of the pathological process, the conducted correlation analysis also confirms this. In this regard, telomerase activity testing can also be used as a marker in clinical practice in CIN monitoring and perspective determination [32, 37]. Sergeeva N.S. and co-authors [38] have proposed the use of the SCC serological marker for Tumor Association, for example, in the treatment and monitoring of patients with CT. Belokrininskaya T.E. and co-authors [19], as well as Podistov Yu.I. and according to the data cited by co - authors [20], the high expression of the R53 suppressor-protein in CIN1 indicates its protective function in the process of carcinogenesis, is one of the most important criteria in assessing the degree of lesion, disease development. Alonio L.V. et al. [39] as a result of studies conducted in CIN2,3, The examined patient also found mutations in women known as Ha-ras, which, according to the authors, can be considered as a marker of the rapid development (progression) of the tumor formation process in the body.

A review of the literature found that CT is one of the common diseases. Taking into account the formation of CIN before CT, the early diagnosis of this condition is an urgent problem of Clinical Medicine. It is worth noting that diagnosis methods based on immune mechanisms are widely distributed in CIN diagnosis along with cytological, colposcopic methods. Therefore, the diagnosis of CIN provides the diagnosis of CT, laying the groundwork for the prevention of its development and providing a positive perspective.

## LIST OF USED LITERATURE

1. Старинский В.В. Стратегия и тактика онкослужбы России на современном этапе // Материалы VI съезда онкологов РФ. - Ростов на Дону, 2005. – 166 б.
2. Булгакова С.В. Оценка репродуктивного статуса женщин, перенесших органосберегающие онкологические операции. Автореф. дисс... канд. мед. наук. - Москва, 2007. - 27 б.
3. Мелехова Н.Ю., Иванян А.Н., Харитонова Л.И., Бехтерева И.А. Онкологический потенциал различных патологических состояний шейки матки // Журнал акушерства, женских болезней. - СПб, 2006. - №3. - 61-65 б.
- 4.Мустафаева Ф.А.Кичик чаноқ аъзолари яллиғланиш касалликларида аёллар иммун тизими кўрсаткичларини ўрганиш натижалари//Журнал биомедицины и практики.Тошкент, 2022-№4 С.(43-49).
- 5.Мустафаева Ф.А., Ихтиярова Г.А., Завкибекова Т.К. Прогнозирование специфических иммуноглобулинов к антигенам этиологических агентов при воспалительных заболеваниях органов малого таза у женщин // Проблемы

*Section A-Research paper*

биологии и медицины. – Самарқанд, 2021. - №1(125). - С.54-58 (14.00.00, №19)

6. Новик В.И. Эпидемиология рака шейки матки, факторы риска, скрининг // Практическая онкология. - Москва, 2002. - Т.3. - №3. - 156-165 б.
7. Amant F., Van Calsteren K., Halaska M.J. et al. Gynecologic cancers in pregnancy: Duidelines of an international consensus meeting // J.Gynecol. Cancer. - 2009. - Vol.19. - Р.1-12.
8. Урманчеева А.Ф., Ульрих Е.А. Цервикальные интраэпителиальные неоплазии и беременность // Журнал акушерства, женских болезней. - СПб, 2006. - №4. - 8-10 б.
9. Веснина Е.Л. Современные диагностические возможности в определении неоплазий шейки матки: Обзор // Журнал акушерства, женских болезней. - СПб, 2007. - №2. - 91-97 б.
10. Короленкова Л.И., Брюзгин В.В. Тяжелые цервикальные интраэпителиальные неоплазии (CINII-III/преинвазивный рак) и микрокарцинома шейки матки у беременных // Акушерство и гинекология. - Москва, 2011. - №5. - 68-73 б.
11. Михайлова Н.А., Долгих В.Т., Трещева Т.В. Использование низкоэнергетического лазерного излучения в комплексном лечении женщин с цервикальной интраэпителиальной неоплазией // Эффективная терапия. - СПб, 2006. - Т.12. - №4. - 40-44 б.
12. Berek J.S. Simplification of the now Bethesda 2011 classification system // A. J. Obstet. Gynecol. - 2003. - Vol.188. - N2-5. - P.6-7.
13. Ayhan A. et al. Textbook of gynecological oncology // Gunes Publishing, 2009. - Р.15-20.
14. Урманчеева А.Ф. Гинекологический рак в сочетании с беременностью // Практическая онкология. - Москва, 2009. - Т.10. - №4. - 184-197 б.
15. Серова О.Ф., Зароченцева Н.В., Титченко Л.Н., Белоусова Т.Н. Особенности течения беременности у женщин перенесших инвазивное лечение цервикальных интраэпителиальных неоплазий // Вопросы гинекологии, акушерства и перинатологии. - Москва, 2009. - №1. - 17-21 б.
16. Сидельникова В.М. Привычная потеря беременности. - Москва: Триада-х, 2002. - 166-167 б.
17. Ронина Е.А., Новикова Е.Г., Андреева Ю.Ю. Мелкоклеточный рак шейки матки (клиническое наблюдение) // Российский онкологический журнал. - Москва, 2006. - №5. - 48-50 б.
18. Guillaud M., Cox D., Adler-Storthz K. et al. Exploratory analysis of quantitative histopathology of cervical intraepithelial neoplasia: objectivity,

*Section A-Research paper*

- reproducibility, malignancy-associated changes, and human papillomavirus // *Cytometry A.* - 2004. - Vol.60. - N1. - P.81-89.
19. Бахидзе Е.В. Фертильность, беременность и гинекологический рак. - Москва-СПб, 2004. - 285 б.
20. Белокриницкая Т.Е., Пономарева Ю.Н., Бунина Е.Н., Ломнева Г.М. Некоторые клинико-морфологические особенности цервикальных дисплазий // *Журнал акушерства, женских болезней.* - СПб, 2006. - T.LV. - Вып.2.- 71-75 б.
21. Fukasawa I., Kousaka N., Kun Z., Inaba N. Tumor markers in uterine cancers // *Gan. To. Kagaku. Ryoho.* - 2002. - Vol.29. - N2. - P.333-340.
22. Автандилов Г.Т., Глухова Ю.К., Шабалова И.П. Плоидометрическая диагностика предраковых процессов и рака шейки матки по цитологическим препаратам // *Клиническая лабораторная диагностика.* - Москва, 2004. - №11. - 45-47 б.
23. Трунова Т.В. Компьютерная морфометрия в цитологической диагностике дисплазии эпителия и рака шейки матки // *Онкология.* - Москва, 2003. - T.5. - №4. - 271-274 б.
24. Bocking A., Nguyen V.Q. Diagnostic use of DNA image cytometry in cervical sguamous intraepithelial lesions and invasive carcinoma // *Cancer.* - 2004. - Vol.102. - N1. - P.41-54.
25. Brychtova S., Brychta T., Sediakova E., Kolar Z. Proto-oncogene c-mrbB-2 in uterine cervix carcinogenesis // *Neoplasma* - 2004. - Vol.51. - N2. - P.84-89.
26. Мусеридзе Н.Г., Джугели М.К., Бурхадзе Г.М. Иммуногистохимические особенности при различной степени железистой интраэпителиальной неоплазии шейки матки // V съезд онкологов и радиологов СНГ: материалы съезда. - Ташкент, 2008. – 81 б.
27. Шаптефрань Л.А., Черная Т.Н., Черный А.П. Иммуногистохимическое и электронно-микроскопическое исследование подэпителиальных капилляров при неоплазиях шейки матки // V съезд онкологов и радиологов СНГ: материалы съезда. - Ташкент, 2008. – 89 б.
28. Ваганова И.Г. Апоптоз и пролиферация эпителиоцитов эктоцервикса у больных папилломавирусным и хламидийным цервицитом // *Вопросы онкологии.* - Москва, 2000. - T.46. - №5. - 578-582 б.
29. Золотоверхая Е.А., Шипицына Е.В., Юшманова Е.С., Савичева А.М. Маркеры папилломавирусной инфекции в скрининге рака шейки матки // *Журнал акушерства, женских болезней.* - СПб, 2009. - №4. - 31-39 б.
30. Макацария А.Д., Долгушина Н.В. Беременность, роды и послеродовой период у больных с вирусной инфекцией. - Москва: Триада-х, 2005. - 112 б.

Section A-Research paper

31. Подистов Ю.И. Роль вируса папилломы в развитии предрака и рака шейки матки // Клиническая лабораторная диагностика. - Москва, 2003. - №5. - 44-49 б.
32. Подистов Ю.И., Лактионов К.П., Петровичев Н.Н., Брюзгин В.В. Эпителиальные дисплазии шейки матки (диагностика и лечение). Руководство для врачей. - Москва: «ГЭОТАР-Медиа», 2006. - 136 б.
33. Савичева А.М. Научно-исследовательская работа лаборатории за последние 5 лет // Журнал акушерства, женских болезней. - СПб, 2006. - Т.ЛV. - 13-21 б.
34. Шипицына Е.В., Оржесковская Е.А., Бабкина К.А. Определение вирусной нагрузки и статуса ДНК вируса папилломы человека 16 типа методом ПЦР в реальном времени // Журнал акушерства, женских болезней. - СПб, 2004. - Т.ЛII. - №4. - 26-52 б.
35. Шипицына Е.В., Бабкина К.А., Оржесковская Е.А., Савичева А.М. Папилломавирусная инфекция: факторы риска цервикальной неопластической прогрессии // Журнал акушерства, женских болезней. - 2004. - Т.ЛII. - №3. - 34-41 б.
36. Городецкая Е.Е., Саешников П.Г., Бударина С.О. Значение исследования уровня онкобелка E7 вируса папилломы человека 16-го и 18-го типов в цервикальном материале в диагностике неопластических образований шейки матки // Молекулярная биология. - Москва, 2010. - №5. - 9-12 б.
37. Сергеева Н.С., Дубовицкая О.Б., Маршугина Н.В. Опухоль ассоциированный серологический маркер SCC на этапах лечения и в мониторинге больных раком шейки матки // Российский онкологический журнал. - Москва, 2004. - №4. - 12-14 б.
38. Alonio L.V., Picconi M.A., Delbert D. et al. Ha-ras ontogeny mutation associated to progression of papillomavirus induced lesions of uterine cervix // J. Clin. Virol. - 2003. - Vol.27. - N3. - P.263-269.